Roswell Park Cancer Vaccine Trial Shows Longer Survival for some Patients

Roswell Park Glioblastoma Vaccine Misses Main Survival Goal, but Patients 65 and Younger Lived Longer in Unpublished Data

SurVaxM missed its main survival goal in glioblastoma but helped patients 65 and younger in early data. What families should know about the vaccine.

Exclusive: Promising Brain Cancer Vaccine Gives Hope to Patients

Each year, some 15,000 Americans are diagnosed with glioblastoma, the deadliest form of brain cancer. Only 7% live more than five years but a new vaccine still in development could offer patients more time. NBC’s Anne Thompson reports for TODAY.

Roswell Park cancer vaccine trial shows longer survival for some patients

BUFFALO, N.Y. (WIVB) — A cancer vaccine being tested by Roswell Park's cancer center is showing longer survival rates for some patients with glioblastoma, according to test results released Wednesday. The vaccine, called SurVaxM and developed by MimiVax Inc. and Roswell Park, was administered to 233 glioblastoma patients across 11 cancer centers across the country. [...]

Experimental vaccine shows promise against deadly brain cancer in some patients

When Tracey Kassman was diagnosed with glioblastoma in 2022 at age 64, she thought her life was over.

Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma

SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.

Vaccine for deadly brain cancer narrowly misses goal in key trial

A brain cancer effort more than a decade in the making has culminated in a disappointing study result — but researchers behind it are contending there’s enough of a promising signal to give certain patients with ...